HRP20230585T1 - Novi derivati amino pirimidina - Google Patents

Novi derivati amino pirimidina Download PDF

Info

Publication number
HRP20230585T1
HRP20230585T1 HRP20230585TT HRP20230585T HRP20230585T1 HR P20230585 T1 HRP20230585 T1 HR P20230585T1 HR P20230585T T HRP20230585T T HR P20230585TT HR P20230585 T HRP20230585 T HR P20230585T HR P20230585 T1 HRP20230585 T1 HR P20230585T1
Authority
HR
Croatia
Prior art keywords
alkyl
optionally substituted
halogen
hydrogen
cyclopropyl
Prior art date
Application number
HRP20230585TT
Other languages
English (en)
Croatian (hr)
Inventor
Daniela Angst
Francois Gessier
Anna Vulpetti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20230585T1 publication Critical patent/HRP20230585T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
HRP20230585TT 2013-11-29 2014-11-28 Novi derivati amino pirimidina HRP20230585T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29
EP20158961.1A EP3689865B1 (en) 2013-11-29 2014-11-28 Novel amino pyrimidine derivatives

Publications (1)

Publication Number Publication Date
HRP20230585T1 true HRP20230585T1 (hr) 2023-09-01

Family

ID=49674216

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20230585TT HRP20230585T1 (hr) 2013-11-29 2014-11-28 Novi derivati amino pirimidina
HRP20171999TT HRP20171999T1 (hr) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20171999TT HRP20171999T1 (hr) 2013-11-29 2014-11-28 Novi derivati aminopirimidina
HRP20200775TT HRP20200775T1 (hr) 2013-11-29 2020-05-12 Novi derivati amino-pirimidina

Country Status (42)

Country Link
US (6) US9512084B2 (enExample)
EP (5) EP3689865B1 (enExample)
JP (2) JP6342495B2 (enExample)
KR (2) KR102421388B1 (enExample)
CN (2) CN110172056B (enExample)
AP (1) AP2016009158A0 (enExample)
AR (1) AR098549A1 (enExample)
AU (1) AU2014356069B2 (enExample)
BR (1) BR112016010397B1 (enExample)
CA (1) CA2926908C (enExample)
CL (1) CL2016001055A1 (enExample)
CR (1) CR20160244A (enExample)
CU (1) CU24384B1 (enExample)
CY (3) CY1119705T1 (enExample)
DK (3) DK3299368T3 (enExample)
EA (1) EA031218B1 (enExample)
EC (1) ECSP16054826A (enExample)
ES (4) ES2791525T3 (enExample)
FI (1) FI3689865T3 (enExample)
HR (3) HRP20230585T1 (enExample)
HU (3) HUE062248T2 (enExample)
IL (1) IL244943B (enExample)
JO (1) JO3314B1 (enExample)
LT (3) LT3074386T (enExample)
MA (1) MA39055B1 (enExample)
MX (1) MX367911B (enExample)
MY (2) MY179059A (enExample)
NO (1) NO3074386T3 (enExample)
NZ (1) NZ718835A (enExample)
PE (1) PE20160869A1 (enExample)
PH (1) PH12016500791A1 (enExample)
PL (3) PL3074386T3 (enExample)
PT (3) PT3074386T (enExample)
RS (3) RS64275B1 (enExample)
SI (3) SI3689865T1 (enExample)
SV (1) SV2016005206A (enExample)
TN (1) TN2016000128A1 (enExample)
TW (1) TWI652261B (enExample)
UA (1) UA117256C2 (enExample)
UY (1) UY35858A (enExample)
WO (1) WO2015079417A1 (enExample)
ZA (1) ZA201602275B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CN111514283B (zh) 2014-04-07 2025-10-14 诺华股份有限公司 使用抗cd19嵌合抗原受体治疗癌症
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP3172234B1 (en) 2014-07-21 2020-04-08 Novartis AG Treatment of cancer using a cd33 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
AU2015305531B2 (en) 2014-08-19 2021-05-20 Novartis Ag Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US10774388B2 (en) 2014-10-08 2020-09-15 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
EP3280795B1 (en) * 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CA2981751A1 (en) 2015-04-08 2016-10-13 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
EP4643874A2 (en) 2015-12-22 2025-11-05 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
KR20180118175A (ko) 2016-03-04 2018-10-30 노파르티스 아게 다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
CA3031542A1 (en) 2016-07-20 2018-01-25 University Of Utah Research Foundation Cd229 car t cells and methods of use thereof
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
CN110290807B (zh) 2016-12-03 2024-06-14 朱诺治疗学股份有限公司 确定car-t细胞给药的方法
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11413310B2 (en) 2017-06-02 2022-08-16 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
TW201932482A (zh) 2017-11-01 2019-08-16 美商奇諾治療有限公司 對b細胞成熟抗原具特異性之嵌合抗原受體及編碼聚核苷酸
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
KR20200116081A (ko) 2017-12-01 2020-10-08 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포의 투약 및 조절 방법
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
CN112204048A (zh) 2017-12-15 2021-01-08 朱诺治疗学股份有限公司 抗cct5结合分子及其使用方法
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
MX2020013443A (es) 2018-06-13 2021-02-26 Novartis Ag Receptores de antigeno quimerico de bcma y usos de los mismos.
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
IL281025B2 (en) 2018-08-29 2024-12-01 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
BR112021007626A2 (pt) 2018-11-01 2021-10-13 Juno Therapeutics, Inc. Receptores antigênicos quiméricos específicos pa-ra receptor acoplado à proteína g receptor de classe c, grupo 5, membro d (gprc5d)
SG11202105084VA (en) 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
FI3886875T3 (fi) 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
MX2021009087A (es) 2019-01-29 2021-09-08 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2020234779A1 (en) * 2019-05-23 2020-11-26 Novartis Ag Crystalline forms of a btk inhibitor
PL3972603T3 (pl) 2019-05-23 2025-02-03 Novartis Ag Sposoby leczenia zespołu sjögrena przy użyciu inhibitora kinazy tyrozynowej brutona
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
AU2020280272B2 (en) 2019-05-23 2025-07-24 Novartis Ag Methods of treating Chronic Spontaneous Urticaria using a Bruton's tyrosine kinase inhibitor
US20230121818A1 (en) * 2019-12-23 2023-04-20 Biogen Ma Inc. Btk inhibitors
CN115916223A (zh) 2020-04-10 2023-04-04 朱诺治疗学股份有限公司 与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
CA3185469A1 (en) 2020-08-14 2022-02-17 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
WO2022033569A1 (zh) * 2020-08-14 2022-02-17 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
WO2022162513A1 (en) 2021-01-26 2022-08-04 Novartis Ag Pharmaceutical composition
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
EP4395779A1 (en) 2021-09-03 2024-07-10 Novartis AG Lou064 for treating multiple sclerosis
MX2024007354A (es) 2021-12-14 2024-06-28 Novartis Ag Metodos de tratamiento usando lou064.
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
EP4543923A1 (en) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20250047766A (ko) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
CN119998265A (zh) 2022-09-30 2025-05-13 诺华股份有限公司 用于生产瑞布替尼的合成方法和中间体
WO2024129778A2 (en) 2022-12-13 2024-06-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
TW202515850A (zh) * 2023-09-22 2025-04-16 大陸商江蘇恆瑞醫藥股份有限公司 雜芳基類化合物、其製備方法及其在醫藥上的應用
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
US20030040461A1 (en) 2000-10-23 2003-02-27 Mcatee C. Patrick Modulators of Bruton'sTyrosine Kinase and Bruton's Tyrosine Kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related diseases states
MXPA03004037A (es) 2000-11-07 2003-08-19 Novartis Ag Derivados de indolilmaleimida como inhibidores de proteina de cinasa c.
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7365096B2 (en) 2002-12-09 2008-04-29 Board Of Regents, The University Of Texas System Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
ES2467160T3 (es) 2003-05-19 2014-06-12 Irm Llc Compuestos y composiciones inmunosupresores
ES2389203T3 (es) 2004-01-12 2012-10-24 Ym Biosciences Australia Pty Ltd Inhibidores de quinasa selectivos
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
WO2008033858A2 (en) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
HUE028086T2 (en) 2006-09-22 2016-11-28 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
EP2550976A3 (en) 2007-03-14 2013-04-03 Bionsil S.r.l. Modulator compounds of the drug resistance in epithelial tumour cells
AU2009244291B2 (en) 2008-05-06 2014-02-13 Genentech, Inc. Substituted amides, method of making, and use as Btk inhibitors
MX2010013478A (es) 2008-07-02 2010-12-20 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de cinasa.
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2421854B1 (en) 2009-04-24 2014-07-23 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
BR112012021453A2 (pt) * 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
JP6147727B2 (ja) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼｂｔｋ阻害剤としての置換ｎ−（３−（ピリミジン−４−イル）フェニル）アクリルアミド類似体
JP6068451B2 (ja) 2011-05-17 2017-01-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア キナーゼ阻害剤
HUE059230T2 (hu) 2011-06-10 2022-10-28 Merck Patent Gmbh Vegyületek és eljárások BTK-inhibitor aktivitású pirimidin és piridin vegyületek elõállítására
MX2014000130A (es) 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
CN103732596B (zh) 2011-07-08 2016-06-01 诺华股份有限公司 吡咯并嘧啶衍生物
EP2742138B1 (en) 2011-08-09 2020-06-24 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
BR112014009276A8 (pt) 2011-10-19 2017-06-20 Pharmacyclics Inc uso de inibidores de tirosina quinase de bruton (btk)
AR088570A1 (es) 2011-10-28 2014-06-18 Celgene Avilomics Res Inc Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
HK1200816A1 (en) 2011-12-09 2015-08-14 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
EP2824099A4 (en) 2012-03-09 2015-11-11 Carna Biosciences Inc NOVEL TRIAZINE DERIVATIVE
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
US9133134B2 (en) 2012-05-16 2015-09-15 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20140045813A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as btk inhibitors
EP3680238A1 (en) 2012-10-04 2020-07-15 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
RS60251B1 (sr) 2020-06-30
PH12016500791B1 (en) 2016-06-13
PL3074386T3 (pl) 2018-03-30
BR112016010397B1 (pt) 2023-04-11
US20200010426A1 (en) 2020-01-09
US20220041561A1 (en) 2022-02-10
CY1122924T1 (el) 2021-10-29
SI3689865T1 (sl) 2023-07-31
FI3689865T3 (fi) 2023-06-12
HUE049794T2 (hu) 2020-10-28
IL244943B (en) 2020-04-30
ES2791525T3 (es) 2020-11-04
MX2016006908A (es) 2016-08-17
LT3689865T (lt) 2023-07-10
EP4606377A2 (en) 2025-08-27
EP4606377A3 (en) 2025-11-26
PL3299368T3 (pl) 2020-08-10
MA39055B1 (fr) 2018-10-31
ECSP16054826A (es) 2017-10-31
UY35858A (es) 2015-06-30
SV2016005206A (es) 2016-11-21
IL244943A0 (en) 2016-05-31
US20180251432A1 (en) 2018-09-06
HK1252317A1 (en) 2019-05-24
JP2018141005A (ja) 2018-09-13
HUE062248T2 (hu) 2023-10-28
TN2016000128A1 (en) 2017-10-06
RS64275B1 (sr) 2023-07-31
KR20160088877A (ko) 2016-07-26
US20150152068A1 (en) 2015-06-04
EP3299368B1 (en) 2020-02-26
US20160235746A1 (en) 2016-08-18
EA031218B1 (ru) 2018-12-28
US10457647B2 (en) 2019-10-29
HRP20200775T1 (hr) 2020-07-24
LT3074386T (lt) 2017-12-27
MY191381A (en) 2022-06-22
CN105683181A (zh) 2016-06-15
EP4219478A1 (en) 2023-08-02
SI3299368T1 (sl) 2020-07-31
MY179059A (en) 2020-10-26
AP2016009158A0 (en) 2016-04-30
AU2014356069B2 (en) 2017-06-15
LT3299368T (lt) 2020-05-25
TWI652261B (zh) 2019-03-01
NZ718835A (en) 2021-12-24
HK1223368A1 (en) 2017-07-28
CN110172056A (zh) 2019-08-27
US9512084B2 (en) 2016-12-06
JP2016538313A (ja) 2016-12-08
DK3689865T3 (en) 2023-06-19
DK3299368T3 (da) 2020-05-25
CU24384B1 (es) 2019-03-04
EA201691125A1 (ru) 2016-09-30
EP4219478B1 (en) 2025-06-11
JP6667573B2 (ja) 2020-03-18
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
CA2926908C (en) 2021-10-26
HUE037588T2 (hu) 2018-09-28
NO3074386T3 (enExample) 2018-03-10
SI3074386T1 (en) 2018-02-28
UA117256C2 (uk) 2018-07-10
EP3689865B1 (en) 2023-03-29
AU2014356069A1 (en) 2016-05-05
KR102421388B1 (ko) 2022-07-18
ES2655527T3 (es) 2018-02-20
DK3074386T3 (en) 2018-01-22
EP3074386B1 (en) 2017-10-11
PT3689865T (pt) 2023-06-16
HRP20171999T1 (hr) 2018-02-09
AR098549A1 (es) 2016-06-01
PT3074386T (pt) 2017-11-15
PE20160869A1 (es) 2016-09-08
MX367911B (es) 2019-09-11
KR20220044370A (ko) 2022-04-07
US11673868B2 (en) 2023-06-13
WO2015079417A1 (en) 2015-06-04
MA39055A1 (fr) 2018-02-28
RS56657B1 (sr) 2018-03-30
CY1119705T1 (el) 2018-06-27
ZA201602275B (en) 2017-08-30
EP3074386A1 (en) 2016-10-05
CA2926908A1 (en) 2015-06-04
CL2016001055A1 (es) 2016-10-28
PL3689865T3 (pl) 2023-07-31
ES2947770T3 (es) 2023-08-18
CU20160078A7 (es) 2016-09-30
BR112016010397A8 (pt) 2020-04-22
KR102380539B1 (ko) 2022-03-29
US11180460B2 (en) 2021-11-23
CN110172056B (zh) 2022-04-19
CR20160244A (es) 2016-07-29
EP3299368A1 (en) 2018-03-28
CN105683181B (zh) 2019-04-23
TW201609666A (zh) 2016-03-16
PT3299368T (pt) 2020-05-28
PH12016500791A1 (en) 2016-06-13
ES3040769T3 (en) 2025-11-04
CY1126056T1 (el) 2023-11-15
US20230312483A1 (en) 2023-10-05
JP6342495B2 (ja) 2018-06-13

Similar Documents

Publication Publication Date Title
HRP20230585T1 (hr) Novi derivati amino pirimidina
HRP20211583T1 (hr) Tienopiridini i benzotiofeni korisni kao irak4 inhibitori
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
HRP20210472T1 (hr) Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4
PE20121327A1 (es) Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello
SI3008053T1 (en) PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
JP2016516724A5 (enExample)
HRP20221043T1 (hr) Derivat oksi-fluoropiperidina kao inhibitor kinaze
NZ595989A (en) Heteroaryl compounds and uses thereof
PE20140865A1 (es) Inhibidores de la tirosina-quinasa de bruton
HRP20180411T1 (hr) Predlijekovi inhibitora aminokinazolinske kinaze
JP2017530185A5 (enExample)
JP2020524687A5 (enExample)
PE20140226A1 (es) Compuestos de triazolopiridina
PE20140240A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
AR081197A1 (es) Lactamas sustituidas con piperidinil o como moduladores de gpr 119
JP2014516074A5 (enExample)
HRP20141199T1 (hr) Kombinacija od spoja glyt1 s antipsihoticima
HRP20201158T1 (hr) Derivati indolin-2-ona
HRP20120762T1 (hr) Tetrasupstituirani piridazini kao inhibitori hedgehog puta
HRP20171031T1 (hr) Supstituirani tetrahidrokarbazol i karbazol karboksamid spojevi koji se koriste kao inhibitori kinaze
AR082827A1 (es) Compuestos de aril-metiloxi-benzamida, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento util para el tratamiento o la profilaxis de la enfermedad de parkinson
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora